PD1 AND PDL1 ANTIBODIES AND VACCINE COMBINATIONS AND USE OF SAME FOR IMMUNOTHERAPY

• US 20170007693A1
• Filed: 01/06/2015
• Published: 01/12/2017
• Est. Priority Date: 01/06/2014
• Status: Active Grant

• Current Assignee: Inovio Pharmaceuticals, Inc., Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Original Assignee: Inovio Pharmaceuticals, Inc., Trustees Of The University Of Pennsylvania (University of Pennsylvania)
• Inventors: MUTHUMANI, Karupplah, SARDESAI, Niranjan, WEINER, David
• Granted Patent: US 10,835,595 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2039/55516 Proteins; Peptides
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0005 Vertebrate antigens from snakes A61K39/38
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/001153 Wilms tumor 1 [WT1]
• CPC Class Codes: A61K 39/001156 Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
• CPC Class Codes: A61K 39/001157 Telomerase or TERT [telomerase reverse transcriptase]
• CPC Class Codes: A61K 39/001186 MAGE
• CPC Class Codes: A61K 39/001188 NY-ESO
• CPC Class Codes: A61K 39/001189 PRAME
• CPC Class Codes: A61K 39/001193 Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61M 2037/0007 having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
• CPC Class Codes: A61N 1/327 for enhancing the absorption properties of tissue, e.g. by electroporation
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/005 : from viruses
• CPC Class Codes: C07K 16/2827 : against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C12N 2710/20034 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 7/00 : Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed herein is a vaccine comprising an antigen and PD1 antibody and/or PDL1 antibody. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof.

Claims

1. A composition for enhancing an immune response against an antigen in a subject in need thereof, comprising:

a) PD1 antibody or PDL1 antibody, or combination thereof, and

b) a synthetic antigen capable of generating an immune response in the subject, or an immunogenic fragment or variant thereof.

2. The composition of claim 1 wherein the synthetic antigen is an isolated DNA that encodes for the antigen.

3. The composition of claim 2 wherein the synthetic antigen is selected from the group consisting of:

hTERT, prostate, WT1, tyrosinase, NYES01, PRAME, MAGE, CMV, herpes, HIV, HPV, HCV, HBV, influenza, RSV, Plasmodium falciparum, and C. difficle.

4. The composition of claim 3, wherein the HPV antigen is E6 and E7 domains of subtypes selected from the group consisting of:

HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV52, and HPV58, and a combination thereof.

5. The composition of claim 3, wherein the HIV antigen is selected from the group consisting of:

Env A, Env B, Env C, Env D, B Nef-Rev, and Gag, and a combination thereof.

6. The composition of claim 3, wherein the influenza antigen is selected from the group consisting of:

H1 HA, H2 HA, H3 HA, H5 HA, BHA antigen, and any combination thereof.

7. The composition of claim 3, wherein the Plasmodium falciparum antigen includes a circumsporozoite (CS) antigen.

8. The composition of claim 3, wherein the C. difficle antigen is selected from the group consisting of:

Toxin A, and Toxin B, and a combination thereof.

9. The composition of claim 3, wherein the HCV antigen is selected from the group consisting of:

E1, E2, NS3, NS4a, NS4b, NS5a, and NS5b, and a combination thereof.

10. The composition of claim 3, wherein the HBV antigen is selected from the group consisting of:

surface antigen type A, surface antigen type B, surface antigen type C, surface antigen type D, surface antigen type E, surface antigen type F, surface antigen type G, surface antigen type H, and core antigen, and a combination thereof.

11. The composition of claim 3, wherein the RSV antigen is selected from the group consisting of:

F, G, NS1, NS2, N, M, M2-1, M2-2, P, SH, and L protein, and a combination thereof.

12. The composition of claim 3, wherein the synthetic antigen is hTERT.

13. The composition of claim 3, wherein the prostate antigen is selected from the group consisting of:

PSA, PSMA, STEAP, PSCA, and PAP, and a combination thereof.

14. The composition of claim 3, wherein the synthetic antigen is WT1 antigen.

15. The composition of claim 3, wherein the synthetic antigen is tyrosinase.

16. The composition of claim 3, wherein the synthetic antigen is NYES01.

17. The composition of claim 3, wherein the synthetic antigen is PRAME.

18. The composition of claim 3, wherein the synthetic antigen is a herpes antigen, wherein the herpes is HCMV, HSV1, HSV2, VZV, or CMV, and the herpes antigen is selected from the group consisting of gB, gM, gN, gH, gL, gO, gE, gI, gK, gC, gD, UL128, UL130, UL131A, and UL83.

19. The composition of claim 1, wherein the PD1 antibody and PDL1 antibody is selected from the group consisting of:

nivolumab, pembrolizumab, pidilizumab, BMS-936559, MPDL3280A, MDX1105-01, MEDI4736, and MK-3475.

20. The composition of claim 1, further comprising a pharmaceutically acceptable excipient.

21. A method for increasing an immune response in a subject in need thereof, the method comprising administering the composition of claim 1 to the subject.

22. The method of claim 21, wherein administering the composition comprises an electroporating step.